G-007 CHINESE HYPERTENSION INTERVENTION EFFICACY (CHIEF) STUDY
Wen Wang, Liyuan Ma, Zhu Dingliang, Lin Shu-guang, Shuping Ma, Tang Xinhua, Fanghong Lu, Liangqing Zhang · Journal of Hypertension · 2011
Background The incidence of hypertension-related morbidity is increasing in Chinese population, but the control rates for hypertension are low. The Chinese Hypertension Intervention EFficacy (CHIEF) study is a multicenter, prospective, randomized, open label blinded endpoint evaluation (PROBE) trial. It aims to investigate the optimal treatment strategy for hypertension, to ensure that more patients reach their blood pressure (BP) goals and to reduce cardiovascular events. Patients and Methods Patients will be eligible for inclusion if they have essential hypertension, and are aged 50–79 years with at least one cardiovascular risk factor and provide informed consents. A total of 13,500 patients have been randomly assigned to either low-dose amlodipine + telmisartan group or amlodipine + diuretics group. Those patients with serum cholesterol levels between 4.0 and 6.1mmol/L, will also be randomized to a low-dose statin-based regimen or a standard management regimen. Patients will also be randomly assigned to an intensive lifestyle intervention or a standard intervention according to the community area where the patients live. Study outcomes Primary study outcomes are a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death. The patients will be followed for up to 4 years. Interim results: 13542 patients entered randomly to take amlodipine 2.5mg+ telmishatan 40 mg/d or amlodipine 2.5 mg + diuretics. From 2007 to 2010, BP control rate have maintained 85%, both group. A total of 180 clinical centers in China have taken part in the study and the expected completion date is end 2011. Source of Funding : The Ministry of Sciences and Technology of PRC (2006BAI01A03). Study drugs supplied: Dawnrays Pharmaceutical (Holdings) Limited.